0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence of cardiovascular risk factors in people with epilepsy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Epilepsy has been associated with cardiovascular comorbidity. This study aimed to assess the potential association between cardiovascular risk factors ( CRFs), antiepileptic drugs ( AEDs), and etiology.

          Material and Methods

          A single‐center retrospective epilepsy cohort from the decade of 2004–2013 was assessed. Poisson regression models with robust variance were estimated to obtain CRF prevalence ratios ( PR) according to AED prescription and etiology.

          Results

          After excluding patients in the monotherapy group with vascular etiology or previous cardiovascular events, in the remaining 400 patients, enzyme‐inducer AEDs ( EIAEDs), especially phenytoin ( PHT), were associated with higher prevalence of dyslipidemia ( PRa 1.77, p < .05), compared to valproic acid. No etiology was associated with higher prevalence of any CRF.

          Conclusions

          Patients treated with EIAEDs, especially PHT, had higher prevalence of dyslipidemia.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Somatic comorbidity of epilepsy in the general population in Canada.

          There is a notion that people with epilepsy have substantial and often unrecognized comorbidity of chronic conditions. However, most studies focus on selected patient groups; population-based studies are scarce. We compared the prevalence of chronic somatic conditions in people with epilepsy with that in the general population using Canadian, nationwide, population-based health data. We examined epilepsy-specific and general population health data obtained through two previously validated, independently performed, door-to-door Canadian health surveys, the National Population Health Survey (NPHS, N = 49,000) and the Community Health Survey (CHS, N = 130882), which represent 98% of the Canadian population. The prevalence of epilepsy and 19 other chronic conditions was ascertained through direct inquiry from respondents about physician-diagnosed illnesses. Weighted prevalence, prevalence ratios (PR), and 95% confidence intervals were obtained for the entire population and for males and females separately. Multivariate analyses assessed the strength of association of comorbid conditions with epilepsy as compared with the general population. People with epilepsy had a statistically significant higher prevalence of most chronic conditions than the general population. Conditions with particularly high prevalence in epilepsy (prevalence ratio > or = 2.0) include stomach/intestinal ulcers (PR, CHS 2.5, NPHS 2.7), stroke (PR, CHS 3.9, NPHS 4.7), urinary incontinence (PR, CHS 3.2, NPHS 4.4), bowel disorders (PR, CHS 2.0, NPHS 3.3), migraine (PR, CHS 2.0, NPHS 2.6), Alzheimer's disease (PR, NPHS 4.3), and chronic fatigue (PR, CHS 4.1). There were no gender-specific differences in prevalence of chronic conditions among people with epilepsy. People with epilepsy in the general population, not only those actively seeking medical care, have a high prevalence of chronic somatic comorbid conditions. The findings are consistent across two independent surveys, which show that people with epilepsy in the general population have a two- to five-fold risk of somatic comorbid conditions, as compared with people without epilepsy. This patient-centered comorbidity profile reflects health aspects that are important to people with epilepsy, and indicate the need for a more integrated approach to people with epilepsy. The impact of epilepsy relative to other comorbid conditions requires further analysis, as does the contribution of comorbidity to epilepsy intractability and to differential health care needs. Similarly, it remains to be determined whether the observed comorbidity patterns are specific to epilepsy or simply reflect a pattern that is common to chronic illnesses in general.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein.

            The widely prescribed anticonvulsants phenytoin and carbamazepine are potent inducers of cytochrome P450 enzymes, which are involved in cholesterol synthesis. We sought to determine whether these drugs have an effect on cholesterol and other serological markers of vascular risk. We recruited 34 epilepsy patients taking carbamazepine or phenytoin in monotherapy whose physicians had elected to change treatment to one of the noninducing anticonvulsants lamotrigine or levetiracetam. Fasting blood samples were obtained both before and 6 weeks after the switch to measure serum lipid fractions, lipoprotein(a), C-reactive protein, and homocysteine. A comparator group of 16 healthy subjects underwent the same serial studies. In the epilepsy patients, switch from either phenytoin or carbamazepine produced significant declines in total cholesterol (-24.8 mg/dl), atherogenic (non-high-density lipoprotein) cholesterol (-19.9 mg/dl), triglycerides (-47.1mg/dl) (all p < 0.0001), and C-reactive protein (-31.4%; p = 0.027). Patients who stopped taking carbamazepine also had a 31.2% decline in lipoprotein(a) level (p = 0.0004), whereas those taken off phenytoin had a decrease in homocysteine level (-1.7 micromol/L; p = 0.005). All of these changes were significant when compared with those seen in healthy subjects (p < 0.05). Results were similar whether patients were switched to lamotrigine or levetiracetam. Switching epilepsy patients from the enzyme-inducers carbamazepine or phenytoin to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinically significant amelioration in several serological markers of vascular risk. These findings suggest that phenytoin and carbamazepine may substantially increase the risk for cardiovascular and cerebrovascular disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The somatic comorbidity of epilepsy: a weighty but often unrecognized burden.

              A range of medical and neurologic disorders occurs more frequently in people with epilepsy than in the general population and constitutes its somatic comorbidity. Common examples include cardiac, gastrointestinal, and respiratory disorders; stroke; dementia; and migraine. Alzheimer's disease and migraine are not only more common in epilepsy but are also risk factors for the development of seizures, suggesting a bidirectional association and shared disease mechanisms. Less well-appreciated associations with epilepsy include Parkinson's disease and obstructive sleep apnea. The association between epilepsy and other conditions can be due to a variety of interacting genetic, biologic, and environmental factors. We propose an etiologic classification of comorbidity into uncertain (coincidence or unknown), causal (cause), shared risk factors (common disease mechanisms or shared predisposing risk factors), and resultant (consequence). Co-occurrence of other conditions in a person with epilepsy can complicate diagnosis or have adverse prognostic implications. Management of these conditions may facilitate the treatment of epilepsy, as in the case of obstructive sleep apnea. The presence of somatic disorders in epilepsy is associated with increased health care needs, poorer health-related quality of life, and premature mortality. Prevention, identification, and adequate treatment of comorbid disorders in epilepsy should be an important part of epilepsy management at all levels of care.
                Bookmark

                Author and article information

                Contributors
                rvivanco@imim.es
                Journal
                Brain Behav
                Brain Behav
                10.1002/(ISSN)2157-9032
                BRB3
                Brain and Behavior
                John Wiley and Sons Inc. (Hoboken )
                2162-3279
                20 December 2016
                February 2017
                : 7
                : 2 ( doiID: 10.1002/brb3.2017.7.issue-2 )
                : e00618
                Affiliations
                [ 1 ] Neurovascular Research GroupFundació Institut Mar d'Investigacions Mèdiques (FIMIM) BarcelonaSpain
                [ 2 ]Universitat Autònoma de Barcelona (UAB) BarcelonaSpain
                [ 3 ] Neurology DepartmentParc de Salut Mar BarcelonaSpain
                [ 4 ] Cardiovascular Epidemiology and Genetics Research GroupFundació Institut Mar d'Investigacions Mèdiques (FIMIM) BarcelonaSpain
                Author notes
                [*] [* ] Correspondence

                Rosa Maria Vivanco‐Hidalgo, Neurovascular Research Group, Fundació Institut Mar d'Investigacions Mèdiques (FIMIM), Barcelona, Spain.

                Email: rvivanco@ 123456imim.es

                Article
                BRB3618
                10.1002/brb3.618
                5318371
                28239528
                148491f3-1581-4fe9-9a96-eb9e73294149
                © 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 05 April 2016
                : 03 November 2016
                : 05 November 2016
                Page count
                Figures: 2, Tables: 3, Pages: 6, Words: 4331
                Funding
                Funded by: Rio Hortega Research Fellowship
                Award ID: CM 13/00051
                Funded by: Instituto de Salud Carlos III FEDER
                Award ID: RD12/0042/0020
                Award ID: RD12/0042/0013
                Categories
                Original Research
                Original Research
                Custom metadata
                2.0
                brb3618
                February 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.7 mode:remove_FC converted:20.02.2017

                Neurosciences
                antiepileptic drugs,cardiovascular risk factors,comorbidity,epilepsy
                Neurosciences
                antiepileptic drugs, cardiovascular risk factors, comorbidity, epilepsy

                Comments

                Comment on this article